

Brief Communication: COVID-19 related changes in outpatient CPAP set-up pathways for OSA are linked with decreased 30-day CPAP usage

OSA Alliance:

Chris Turnbull^{1,2}, Martin Allen³, Jennifer Appleby⁴, Richard Brown⁵, Nathalie Bryan³, Ann Cooper³, Brendan Cooper⁶, Cathie Gillooly⁷, James Davidson⁸, Hannah Farley⁴, Ana Gaspar⁹, Gillian Gibbons¹⁰, Beverley Gray⁷, Graham Hill¹¹, Adrian Kendrick¹², Blake Marsh¹, Alison McMillan⁹, Joseph Page⁸, Justin Pepperell⁸, Tim Quinnell¹³, Chris Rogers¹¹, Jane Sexton⁴, Naomi Sheperd⁸, Joerg Steier^{5,14}, James Stockley⁶, John Stradling^{1,2}, Asia Woroszy⁵, Sophie West¹⁵, Susan Wright⁸, Annabel Nickol¹.

- 1. Oxford Department for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK*
- 2. Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK*
- 3. Sleep and ventilation service, University Hospital North Midlands, Stoke on Trent, UK*
- 4. Medical Sciences Division, University of Oxford, Oxford, UK*
- 5. Lane Fox Unit / Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK*
- 6. Lung Function & Sleep, (QEHB Site), University Hospitals Birmingham NHSFT, Birmingham, UK*
- 7. Gloucestershire Hospitals NHS Foundation Trust*
- 8. Musgrove Park Hospital, Taunton*
- 9. East and North Hertfordshire NHS Trust*
- 10. OSA Partnership*
- 11. Sleep Apnoea Trust Association*
- 12. University Hospitals Bristol and Weston NHS Foundation Trust & Department of Physiology, Pharmacology & Neuroscience, University of Bristol*
- 13. Royal Papworth Hospital, Cambridge, UK*
- 14. CHAPS, Faculty of Life Sciences and Medicine, King's College London, London, UK.*
- 15. Newcastle upon Tyne hospitals NHS foundation trust, Newcastle, UK*

Word count 1169 of 1000

Corresponding author: Dr Chris Turnbull christopher.turnbull@ouh.nhs.uk

Department of Respiratory Medicine, Churchill Hospital, Oxford, OX3 7LE, UK

Abstract (99 of 100 words)

The coronavirus pandemic changed continuous positive airway pressure (CPAP) set-up pathways. We evaluated patients commenced on CPAP in 2019 (pre-pandemic) and 2020 (post-first UK wave). Face-to-face (F2F) set-up numbers, with CPAP turned on, decreased from 613 patients (98.9%) in 2019, to six (1.1%) in 2020. In 2020, set-ups were F2F without CPAP turned on (403 (71.1%)), or remote (158 (27.9%)). Pre-pandemic median CPAP usage at first follow-up was 5.4 (2.7-6.9) hours/night and fell by 0.9 hours/night (95% Confidence Interval (CI) 0.5 to 1.2, $p < 0.0001$) in 2020. We found clinically relevant reductions in CPAP usage with pathway changes post COVID.

The coronavirus (COVID-19) pandemic changed the management of patients with obstructive sleep apnoea (OSA) (1). Previously, continuous positive airway pressure (CPAP) was set-up face-to-face (F2F). Experienced healthcare professionals provided education and support, and the CPAP device was switched on. This allowed patients to experience the often initially uncomfortable sensations while under supervision and have any fears allayed (2). However, CPAP is an aerosol-generating procedure and so in-hospital use was limited by COVID-19 infection prevention and control (IPC) guidance (3, 4), meaning it was not possible to routinely conduct face-to-face CPAP trials with the device switched on. The pandemic triggered other pathway changes, including the use of home sleep studies, and remote clinician consultation, monitoring, and follow-up appointments. The impact of these pathway changes is not known, and we aimed to see their effect on CPAP usage.

We conducted a multi-centre retrospective service evaluation of secondary care sleep units. We included consecutive patients commenced on CPAP in July-August 2019 (pre-pandemic) and July-August 2020 (post UK first-wave).

Primarily we evaluated the hours of CPAP usage on 30 nights prior to first follow-up in 2020 compared to 2019. Change in hours of usage was modelled using linear regression and expressed as mean (95% confidence interval (95%CI)) and adjusted for potential confounders of age, gender, ethnicity, centre, log transformed 4% oxygen desaturation index (ODI) and baseline Epworth Sleepiness Score (ESS). Exploratory evaluations compared the difference in CPAP usage between F2F set-ups without CPAP turned on and that of entirely remote set-ups in 2020, and compared CPAP usage by time from sleep study to CPAP set-up in 2019 and 2020 separately.

Secondarily, we evaluated changes in ESS, CPAP adherence (proportion of patients with CPAP usage >4 hours/night on ≥70% of nights), and the number of sleep clinic contacts made in the first month.

Results

In 2019 and 2020 respectively, 620 and 567 patients were included from eight centres (*Table 1*). There were differences in populations between centres in the baseline ODI and ESS. The median ODI by centre ranged from 14.7 /hour (IQR 11.2-33.4) to 29.1/hour (IQR 17.0-44.9) and median baseline ESS ranged from 9 (IQR 5-13) to 14 (IQR 9-16) points. The mean age was comparable between centres, ranging from 51.2±12.9 to 56.3±14.5 years.

In 2019, CPAP set-up was F2F with CPAP machine turned on in 613 patients (98.9%). By contrast, in 2020, only six patients (1.1%) had F2F set-up with CPAP turned on, while 403 (71.1%) had F2F set-up without CPAP being turned on, and 158 (27.9%) had entirely remote set-up.

	2019	2020
Number	620	567
Age (years)	53.4±13.6	53.4±13.3
Gender		
<i>Female</i>	206 (33.2%)	185 (32.6%)
<i>Male</i>	414 (66.8%)	380 (67.0%)
Ethnicity		
<i>White</i>	476 (76.8%)	383 (67.5%)
<i>Asian</i>	18 (2.9%)	12 (2.1%)
<i>Black</i>	10 (1.6%)	10 (1.8%)
<i>Other</i>	7 (1.2%)	5 (0.9%)
<i>Unknown</i>	109 (17.6%)	157 (27.7%)
BMI (kg/m ²)	34.9 (30.6, 41.0)	34.8 (29.5, 40.4)
ESS	11.2±5.5	11.8±5.2
ODI (/hour)	23.0 (14.1, 43.0)	21.5 (13.0, 41.8)
AHI (/hour)	25.5 (15.0, 40.4)	25.7 (14.5, 46.8)

Table 1: Baseline characteristics from patients. Data are expressed as mean ± standard deviation, median (first quartile, third quartile) or number (percentage), as appropriate. AHI=Apnoea Hypopnoea Index, BMI=body mass index, ESS=Epworth sleepiness score, ODI=oxygen desaturation index ≥4%.

Sleep study methods were similar in 2019 vs. 2020; home polygraphy 378 (61.0%) vs 328 (57.8%), laboratory polygraphy/polysomnography 85 (13.7%) vs. 92 (16.2%) and pulse oximetry 142 (22.9%) vs. 131 (23.1%; $\chi^2=1.9$, df=3, p=0.59). Time from sleep study to CPAP set-up increased in 2020 to a median (first quartile, third quartile) of 141 (35, 202) days from 76 (47, 105) days in 2019 (mean difference 45 days; 95%CI 35 to 55; p<0.0001). Time to first follow-up following commencement on CPAP decreased in 2020 to a median of 22 (15, 31) days, from 30 (17, 38) days in 2019 (mean difference -11 days; 95%CI -15 to -6; p<0.0001). Telephone follow-up increased from 21% to 88% within the studied period (*Figure 1*).

Median CPAP use was 5.4 (2.7-6.9) hours/night (h/n) in 2019 and 4.2 (1.4-6.1) h/n in 2020, falling by 0.9 h/n (95%CI 0.5 to 1.2, p<0.0001) in 2020. The result was similar following adjustment for potential confounders (-0.6 h/n, 95%CI -0.3 to -1.2, p=0.0006, n=871). In 2020, CPAP usage with remote set-up was lower compared to F2F set-up (-0.6 h/n, 95%CI -1.1 to -0.1, p=0.03, n=438). There were no

significant differences in mean CPAP usage by quartile of time from sleep study to CPAP set-up in either 2019 (Quartile 1 (Q1) 4.7 ± 2.6 h/n, Q2 4.9 ± 2.6 h/n, Q3 4.8 ± 2.5 h/n, Q4 4.3 ± 2.8 h/n; $F=0.86$, $df=3$, $p=0.46$, $n=479$) or 2020 (Q1 4.3 ± 2.7 h/n, Q2 4.1 ± 2.5 h/n, Q3 4.1 ± 2.8 h/n, Q4 3.6 ± 2.7 h/n; $F=1.78$, $df=3$, $p=0.15$, $n=443$).

In 2019, 244 of 458 patients were adherent with CPAP (53.3%, 95%CI 48.7 to 57.8%) falling to 202 of 490 in 2020 (41.2%, 95%CI 36.9% to 45.6%; $\chi^2=13.8$, $df=1$, $p=0.0002$). Data were frequently missing for the ESS (56%) and sleep clinic contacts (40%) and, as such, we have not stated formal statistical comparisons for these outcomes.

Discussion

In our multi-centre, UK-based service evaluation, pathway changes to CPAP set-up due to COVID-19 related IPC procedures were linked with clinically relevant reductions in CPAP usage. In 2020, entirely remote CPAP set-up was associated with low usage.

To our knowledge, there have been no studies assessing the effect of the COVID-19 pandemic on CPAP usage in those newly commencing CPAP. Small increases in CPAP usage during COVID-19 lockdowns have been reported in established users (5, 6) . In contrast we found lower CPAP usage in patients newly started on CPAP after the first wave of the COVID-19 pandemic.

The reasons why changes to CPAP pathways in 2020 were associated with reduced usage are not clear. The key changes were initial remote consultations, and either remote set-up or in-person set-up without CPAP being turned on. Remote set-up was associated with particularly low usage. Possible reasons for this include reduced personal interaction and less educational provision. Remote CPAP set-up has not been previously studied, unlike remote follow-up with telemonitoring which increases adherence (7, 8). Therefore, the increasing use of remote follow-up we observed in 2020 was unlikely to have undermined CPAP usage.

There were large delays in CPAP set-up in 2020, meaning that treatment was often delayed beyond the national 18-week referral to treatment target. Delayed CPAP set-up may have contributed to low CPAP usage, alongside pathway changes, however, time from sleep study to CPAP set-up was not associated with CPAP usage in 2019 or 2020.

There are strengths and limitations to our service evaluation. We included multiple sites across the UK and captured consecutive patients starting CPAP, increasing generalisability. However, the retrospective design led to a high proportion of missing data for ESS scores and sleep clinic contacts, precluding analysis of these outcomes. There were many different changes to CPAP set-up pathways and variation in practice across centres meaning that our study cannot determine the cause of lower CPAP use in 2020. Whilst we have discussed some of the factors which may have influenced CPAP usage, we cannot account for other confounders that might have influenced CPAP usage.

Nevertheless, our results demonstrate a concerning fall in CPAP usage associated with pathway changes for the post-COVID era, suggesting an urgent need to identify which components are critical to promoting CPAP adherence. Pathway changes were widespread, including remote physician consultations, home sleep studies, stopping face-to-face set-up with CPAP turned on, and remote follow-up. Whilst we do not know the individual impact of each change, lower CPAP usage with entirely remote set-up suggests that key elements of face-to-face CPAP set-up are critical. Going forward, it is essential we do not automatically replace traditional pathways with new methods of CPAP set-up, unless there is evidence of non-inferiority.

Acknowledgments

We would like to acknowledge the staff at all centres for their help in the conduct of this service evaluation.

Competing Interests

Chris Turnbull declares consulting fees from Bayer, outside the scope of this work. Gillian Gibbons declares grant funding from ResMed UK and travel expenses from Wychwood Communications Limited, both outside the scope of this work. There are no other relevant conflicts of interest.

Funding

This service evaluation was not specifically funded.

Contributor statement

The study was conceived and conducted by all authors. Data and statistical analysis, literature search, and initial manuscript preparation was performed by CDT. All authors reviewed and approved the final manuscript.

References

1. Report Service Evaluation "Impact of COVID-19 on UK Sleep Services" 2021 [03/11/2021]. Available from: <https://www.sleepsociety.org.uk/wp-content/uploads/2020/10/BSS-RC-Service-Review-01-10-2020-002.pdf>.
2. Stradling JR, Hardinge M, Smith DM. A novel, simplified approach to starting nasal CPAP therapy in OSA. *Respir Med*. 2004;98(2):155-8.
3. ARTP. ARTP COVID-19 GROUP: Practical guidance for increasing Lung Function and Sleep activity during COVID-19 Endemic Phase. 2020.
4. Craig SE, West SD, Alliance O. Guidance regarding coronavirus (COVID-19) and Obstructive Sleep Apnoea (OSA): for people who routinely use continuous positive airway pressure (CPAP), their families and health care workers, 16 December 2020. 2020.
5. Attias D, Pepin JL, Pathak A. Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients. *Eur Respir J*. 2020;56(1).
6. Bertelli F, Suehs CM, Mallet JP, Court-Fortune I, Gagnadoux F, Borel JC, et al. Did COVID-19 impact Positive Airway Pressure adherence in 2020? A cross-sectional study of 8477 patients with sleep apnea. *Respir Res*. 2022;23(1):46.
7. Hwang D, Chang JW, Benjafield AV, Crocker ME, Kelly C, Becker KA, et al. Effect of Telemedicine Education and Telemonitoring on Continuous Positive Airway Pressure Adherence. The Tele-OSA Randomized Trial. *Am J Respir Crit Care Med*. 2018;197(1):117-26.
8. Schoch OD, Baty F, Boesch M, Benz G, Niedermann J, Brutsche MH. Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea. A Randomized, Controlled Study. *Ann Am Thorac Soc*. 2019;16(12):1550-7.

Figure 1: Method of first follow-up in 2019 and 2020. There was significant difference in the proportions of face-to-face, telephone, and video follow-up from 2019 to 2020 ($\chi^2=692.7$, $df=3$, $p<0.0001$).